Status Epilepticus
📧 Sign up to get email alerts when something new happens for Status Epilepticus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-10-02FDA Approved: LORAZEPAM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Lorazepam from Amneal Pharmaceuticals LLC. The approval updates labeling/indication for the Lora…
-
FDA approval · 2020-08-28FDA Approved: FOSPHENYTOIN — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for fosphenytoin sodium (Fosphenytoin) from Fresenius Kabi USA, LLC. The action confirms an approved…
-
FDA approval · 2020-08-07FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DILANTIN Extended Phenytoin Sodium filed by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan [Phase 3]
Phase 3 open-label study of Midazolam Hydrochloride Oromucosal Solution in children with convulsive status epilepticus completed; results po…
-
CLINICAL_TRIALS trial_result · 2020-02-28Clinical Trial Update: Established Status Epilepticus Treatment Trial [Phase 3]
Phase 3 trial evaluating treatment for benzodiazepine-refractory status epilepticus has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-01-28FDA Approved: CEREBYX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for CEREBYX (fosphenytoin sodium) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus [Phase 4]
Clinical trial update comparing levetiracetam to phenytoin for pediatric status epilepticus in a Phase 4 study; current status is unknown.
-
FDA approval · 2019-02-21FDA Approved: DIAZEPAM — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Diazepam filed by Hospira, Inc. (ANDA 072079).
-
FDA approval · 2019-02-21FDA Approved: DIAZEPAM — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application for diazepam from Hospira, Inc., indicating updated labeling and continued availability under th…
-
CLINICAL_TRIALS trial_result · 2019-02-18Clinical Trial Update: Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan [Phase 3]
Pfizer conducted a Phase 3 trial in Japan to evaluate lorazepam for the treatment of status epilepticus or repetitive status epilepticus. Th…
-
CLINICAL_TRIALS trial_result · 2018-10-11Clinical Trial Update: Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus [Phase 3]
Phase 3 trial comparing lorazepam, clonazepam, and clonazepam plus fosphenytoin for out-of-hospital generalized status epilepticus has compl…
-
CLINICAL_TRIALS trial_result · 2018-08-28Clinical Trial Update: Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting [Phase 3]
Phase 3 clinical trial update on management of pediatric convulsive status epilepticus in a resource-limited setting has completed.
-
FDA approval · 2018-03-08FDA Approved: FOSPHENYTOIN SODIUM — Supplemental Application (West-Ward Pharmaceuticals Corp)
FDA approved a supplemental application for fosphenytoin sodium submitted by West-Ward Pharmaceuticals Corp. The action updates labeling for…
-
FDA approval · 2017-12-22FDA Approved: LORAZEPAM — Original Application (Aurolife Pharma LLC)
FDA approved Aurolife's original application for lorazepam, a generic benzodiazepine.
-
FDA approval · 2017-10-31FDA Approved: CEREBYX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Cerebyx (fosphenytoin sodium) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2017-10-06Clinical Trial Update: Smartphone Apps for Pediatric Resuscitation [NA]
A completed status update for the pediatric resuscitation smartphone app trial (NCT02958605) sponsored by St. Justine's Hospital, focusing o…
-
CLINICAL_TRIALS withdrawal · 2017-08-29Clinical Trial Update: Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus [Phase 3]
Phase 3 trial evaluating adjunctive levetiracetam, lacosamide, and ketamine for refractory status epilepticus has been withdrawn.
-
CLINICAL_TRIALS research · 2017-08-10Clinical Trial Update: Management of Non Convulsive Status Epilepticus
This entry provides an update on a clinical trial studying the management of non-convulsive status epilepticus. The trial status is currentl…
-
CLINICAL_TRIALS trial_result · 2017-03-14Clinical Trial Update: Ketogenic Diet for Refractory Status Epilepticus [NA]
This clinical trial evaluated the ketogenic diet as a treatment for refractory status epilepticus and related seizures; the study led by Joh…
-
FDA approval · 2017-03-10FDA Approved: CEREBYX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Cerebyx (fosphenytoin sodium) from Pfizer Laboratories Div Pfizer Inc. The approval updates …
-
FDA approval · 2017-03-01FDA Approved: CEREBYX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Cerebyx (fosphenytoin sodium) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2016-09-30Clinical Trial Update: Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus [Phase 2]
Phase 2 trial comparing levetiracetam with sodium valproate in children with refractory generalized convulsive status epilepticus has comple…
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: Evaluation of Therapeutic Hypothermia in Convulsive Status EPILEPTICUS in Adults in Intensive Care [Phase 3]
A Phase 3 clinical trial evaluating therapeutic hypothermia for adults with convulsive status epilepticus in intensive care has completed.
-
FDA approval · 2016-06-16FDA Approved: CEREBYX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Cerebyx (fosphenytoin sodium) submitted by Pfizer Laboratories Div Pfizer Inc, expanding the…
-
CLINICAL_TRIALS trial_result · 2016-05-23Clinical Trial Update: Lorazepam for the Treatment of Status Epilepticus in Children [Phase 1]
This update notes the completion of a Phase 1 trial evaluating lorazepam for the treatment of status epilepticus in children. The study is s…